Cargando…

High tumor burden in non-small-cell lung cancer: A review of the literature

BACKGROUND AND AIM: Lung cancer is the leading cause of cancer death worldwide and the majority of the patients have advanced/metastatic disease on presentation. In clinical practice, several biomarkers and clinical factors are taken into account when choosing the best treatment option in advanced n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabezón-Gutiérrez, Luis, Sereno, María, Cervera-Calero, Raquel, Mielgo-Rubio, Xabier, Higuera, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Whioce Publishing Pte. Ltd. 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741935/ https://www.ncbi.nlm.nih.gov/pubmed/36518549

Ejemplares similares

Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021)

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2
por: Olmedo, Maria Eugenia, et al.
Publicado: (2022)

Immunotherapy in non-small cell lung cancer: Update and new insights
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
por: Aguado, Carlos, et al.
Publicado: (2022)

Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer
por: Moreno-Rubio, Juan, et al.
Publicado: (2020)

“High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept
por: Higuera Gómez, Oliver, et al.
Publicado: (2021)

Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020)

Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020)

Advances and controversies in the management of early stage non-small cell lung cancer
por: Cilleruelo-Ramos, Angel, et al.
Publicado: (2021)

Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
por: Aguado, Carlos, et al.
Publicado: (2022)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story
por: Serrano, Javier, et al.
Publicado: (2021)

Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022)

Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020)

Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
por: Sotelo, Miguel J, et al.
Publicado: (2021)

New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer
por: Luna, Javier, et al.
Publicado: (2021)

Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies
por: Martin, Margarita, et al.
Publicado: (2022)

New perspectives in the management of small cell lung cancer
por: Pangua, Cristina, et al.
Publicado: (2022)

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
por: Cai, Liangliang, et al.
Publicado: (2019)

Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden
por: Muto, Satoshi, et al.
Publicado: (2021)

Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
por: van den Heuvel, Guus R. M., et al.
Publicado: (2021)

Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations
por: Smolle, Elisabeth, et al.
Publicado: (2019)

Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients
por: Yang, Fan, et al.
Publicado: (2023)

The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature
por: Enstone, Ashley, et al.
Publicado: (2017)

Tumor mutational burden in lung cancer: a systematic literature review
por: Willis, Connor, et al.
Publicado: (2019)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Genomic profiling in non-small-cell lung cancer in young patients. A systematic review
por: Viñal, D., et al.
Publicado: (2021)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer
por: Chang, Han, et al.
Publicado: (2019)

Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China
por: Ma, Yuhui, et al.
Publicado: (2020)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non–Small-Cell Lung Cancer
por: Brawley, Otis W., et al.
Publicado: (2021)

Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
por: Stott Bond, Nicole L., et al.
Publicado: (2021)

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer
por: Qiu, Yuan, et al.
Publicado: (2021)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
por: Parikh, Ankur R, et al.
Publicado: (2018)

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
por: Burnett, Heather, et al.
Publicado: (2021)

Coronavirus disease 2019 and lung cancer: where are we?
por: Ocanto, Abrahams, et al.
Publicado: (2023)

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
por: Schatz, Stefanie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aksv54lh7j7rov9mbphv23v6o6